Blade Therapeutics to Present Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022

 

SAN FRANCISCO, August 22, 2022 – Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that the company will present data for cudetaxestat in a poster at the European Respiratory Society (ERS) International Congress 2022, September 4-6, 2022, in Barcelona, Spain. The poster abstract (#PA459), titled “Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis,” is now available (click here). The poster will present on Sunday, September 4, 2022, 8:30 a.m. – 9:00 a.m. CET in session TP-24: Interstitial lung diseases diagnosis in the COVID-19 era: new tools for new challenges. For additional information about the ERS International Congress 2022, please visit the website.

About Cudetaxestat

Cudetaxestat (BLD-0409), which is Blade’s lead investigational medicine, is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial in patients with idiopathic pulmonary fibrosis. Available data from four completed phase 1 studies in more than 200 healthy volunteers showed that cudetaxestat was well tolerated with a demonstrated pharmacokinetic/pharmacodynamic correlation and biomarker activity. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis. Cudetaxestat is an investigational medicine that is not approved for commercial use by the FDA or any other regulatory authority.

About Blade Therapeutics

Blade Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases. The company has deep expertise in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses associated with fibrosis and neurodegeneration. Blade’s focused approach offers the potential to produce disease-modifying, life-saving therapies. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and an inhibitor of dimeric calpains. Visit www.blademed.com for more information and follow Blade on LinkedIn.

Contacts

Michael Blash (Blade) – Media
mblash@blademed.com | +1-650-453-0632

Krishna Gorti, M.D. (Blade) – Investors
kgorti@blademed.com | +1-973-570-9438